Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study

Author:

Westin Shannon N.,Sill Michael W.,Coleman Robert L.,Waggoner Steven,Moore Kathleen N.,Mathews Cara A.,Martin Lainie P.,Modesitt Susan C.,Lee Sanghoon,Ju Zhenlin,Mills Gordon B.,Schilder Russell J.,Fracasso Paula M.,Birrer Michael J.,Aghajanian Carol

Funder

National Cancer Institute

Anderson Cancer Center

NCI

NRG

Andrew Sabin Family Fellowship

MSK Cancer Center

Thomas Jefferson University Cancer Center

NIH SPORE

Thomas Jefferson University

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference40 articles.

1. Cancer statistics;Siegel;CA Cancer J Clin 2017,2017

2. Endometrial cancer: a review and current management strategies: part II;Burke;Gynecol. Oncol.,2014

3. Clinical Practice Guidelines in Oncology;National Comprehensive Cancer Network (NCCN),2017

4. Exploiting the PI3K/AKT pathway for cancer drug discovery;Hennessy;Nat. Rev. Drug Discov.,2005

5. Activation of the PI3K/Akt pathway and chemotherapeutic resistance;West;Drug Resist. Updates,2002

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3